BioSIM 抗人 PD-L1/CD274 抗体 (欧可利单

BioSIM 抗人 PD-L1/CD274 抗体 (欧可利单抗)

产品概述

BioSIM anti-Human PD-L1/CD274 Antibody (Opucolimab Biosimilar) 是一种高特异性科研级抗体，属于生物类似药类别，专为PD-L1/CD274靶点研究而设计。该抗体通过人源化技术制备，具有优异的特异性和亲和力，适用于多种免疫学检测和研究应用。

产品信息

• 产品名称：BioSIM 抗人 PD-L1/CD274 抗体 (欧可利单抗)，生物类似药
• 货号：SIM0612-1mg
• 规格：1mg
• CAS号：2251771-79-4
• 供应商：InvivoCrown
• 产品类型：二抗
• 来源宿主：Humanized
• 反应性：Human

产品特性

• 在无动物成分的设施中生产，确保实验结果的纯净性和可重复性
• 采用体外无蛋白细胞培养技术，减少潜在交叉反应风险
• 经过多步骤纯化过程，包括Protein A或G色谱工艺，确保高纯度
• 人源化设计，降低非特异性结合，提高实验准确性

研究领域与应用

PD-L1/CD274是免疫检查点分子，在肿瘤微环境中发挥免疫调节作用。该抗体适用于以下研究领域：

• 癌症免疫治疗研究：晚期实体瘤、膀胱癌、黑色素瘤等
• 免疫检查点机制研究：探索PD-1/PD-L1通路在肿瘤免疫逃逸中的作用
• 生物标志物开发：评估肿瘤组织中PD-L1表达水平

应用类型

• ELISA：用于定量检测样本中PD-L1蛋白表达水平
• FACS：用于流式细胞术分析细胞表面PD-L1表达
• Functional assay：评估PD-L1/PD-1相互作用对免疫功能的调节作用
• Research in vivo：适用于动物模型研究，评估免疫治疗效果

产品优势

• 作为欧可利单抗的生物类似药，为研究者提供高性价比的科研工具
• 严格的质量控制流程确保批次间一致性
• 适用于多种实验平台，满足不同研究需求
• 人源化设计减少实验背景干扰，提高数据可靠性

注意事项

关于该抗体的免疫原性信息请参考产品说明书。本产品仅限科研使用，不适用于诊断或治疗目的。建议在实验前进行优化实验条件，以获得最佳实验效果。

注意：以上信息可能随着产品优化升级等因素产生变动，具体信息请咨询亚科因公司。

BioSIM Anti-Human PD-L1/CD274 Antibody (Opucolimab Biosimilar)

Product Overview

BioSIM anti-Human PD-L1/CD274 Antibody (Opucolimab Biosimilar) is a highly specific research-grade antibody belonging to the biosimilar category, specifically designed for the study of the PD-L1/CD274 target. Prepared through humanization technology, this antibody has excellent specificity and affinity and is suitable for various immunological detection and research applications.

Product Information

• Product Name: BioSIM anti-Human PD-L1/CD274 Antibody (Opucolimab Biosimilar), Biosimilar
• Product Code: SIM0612-1mg
• Specification: 1mg
• CAS Number: 2251771-79-4
• Supplier: InvivoCrown
• Product Type: Secondary Antibody
• Source Host: Humanized
• Reactivity: Human

Product Features

• Produced in an animal-component-free facility to ensure the purity and reproducibility of experimental results
• Adopts in vitro protein-free cell culture technology to reduce the risk of potential cross-reactions
• Undergoes a multi-step purification process, including Protein A or G chromatography technology, to ensure high purity
• Humanized design reduces non-specific binding and improves experimental accuracy

Research Fields and Applications

PD-L1/CD274 is an immune checkpoint molecule that plays an immunomodulatory role in the tumor microenvironment. This antibody is suitable for the following research fields:

• Cancer Immunotherapy Research: Advanced solid tumors, bladder cancer, melanoma, etc.
• Immune Checkpoint Mechanism Research: Explore the role of the PD-1/PD-L1 pathway in tumor immune evasion
• Biomarker Development: Evaluate the expression level of PD-L1 in tumor tissues

Application Types

• ELISA: Used for quantitative detection of PD-L1 protein expression levels in samples
• FACS: Used for flow cytometry analysis of cell surface PD-L1 expression
• Functional assay: Evaluate the regulatory effect of PD-L1/PD-1 interaction on immune function
• Research in vivo: Suitable for animal model research to evaluate the effect of immunotherapy

Product Advantages

• As a biosimilar of Opucolimab, it provides researchers with a cost-effective research tool
• Strict quality control procedures ensure batch-to-batch consistency
• Suitable for various experimental platforms to meet different research needs
• Humanized design reduces experimental background interference and improves data reliability

Precautions

Please refer to the product manual for the immunogenicity information of this antibody. This product is for research use only and is not suitable for diagnostic or therapeutic purposes. It is recommended to optimize experimental conditions before the experiment to obtain the best experimental results.

Note: The above information may change due to product optimization and upgrading. For specific information, please consult Yakeyin Company.